XOMA Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de XOMA han disminuido a una tasa media anual de -31.4%, mientras que en la industria Biotechs los beneficios crecieron en un 12.7% anualmente. Los ingresos han ido creciendo a una tasa media de 2% al año.

Información clave

-31.4%

Tasa de crecimiento de los beneficios

-24.9%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	2.0%
Rentabilidad financiera	-46.0%
Margen neto	-973.2%
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Is XOMA (NASDAQ:XOMA) Using Debt Sensibly?

Apr 03

Are Investors Undervaluing XOMA Corporation (NASDAQ:XOMA) By 49%?

Sep 01

Bearish: Analysts Just Cut Their XOMA Corporation (NASDAQ:XOMA) Revenue and EPS estimates

Aug 11

XOMA GAAP EPS of -$0.53 misses by $0.37, revenue of $0.98M misses by $3.29M

Aug 04

Forecast: Analysts Think XOMA Corporation's (NASDAQ:XOMA) Business Prospects Have Improved Drastically

May 08

Xoma Gets The Spotlight

Sep 02

Things Look Grim For XOMA Corporation (NASDAQ:XOMA) After Today's Downgrade

Aug 20

We Think The Compensation For XOMA Corporation's (NASDAQ:XOMA) CEO Looks About Right

May 13

Analysts Are More Bearish On XOMA Corporation (NASDAQ:XOMA) Than They Used To Be

Mar 16

Is XOMA Corporation (NASDAQ:XOMA) Popular Amongst Institutions?

Mar 09

Did You Miss XOMA's (NASDAQ:XOMA) Impressive 140% Share Price Gain?

Feb 02

XOMA: A Royalty Aggregator To Watch

Jan 04

XOMA (NASDAQ:XOMA) Has Debt But No Earnings; Should You Worry?

Dec 29

XOMA prices $22M offering of series A cumulative perpetual preferred stock

Dec 11

Could The XOMA Corporation (NASDAQ:XOMA) Ownership Structure Tell Us Something Useful?

Dec 01

XOMA earns $2M milestone payment from Takeda

Nov 16

XOMA receives first royalty payment from Agenus

Nov 11

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero XOMA. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGM:XOMA Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	5	-46	26	0
30 Sep 23	4	-32	26	0
30 Jun 23	4	-31	24	0
31 Mar 23	3	-30	24	0
31 Dec 22	6	-23	23	0
30 Sep 22	40	10	21	0
30 Jun 22	41	10	21	0
31 Mar 22	41	12	19	0
31 Dec 21	38	8	20	0
30 Sep 21	30	1	19	0
30 Jun 21	29	6	18	0
31 Mar 21	29	6	17	0
31 Dec 20	29	9	17	0
30 Sep 20	2	-13	17	0
30 Jun 20	11	-9	20	0
31 Mar 20	11	-10	21	0
31 Dec 19	18	-2	21	0
30 Sep 19	20	-2	21	0
30 Jun 19	12	-8	20	0
31 Mar 19	13	-6	19	0
31 Dec 18	5	-13	19	0
30 Sep 18	9	-11	21	0
30 Jun 18	44	9	24	0
31 Mar 18	53	18	24	0
31 Dec 17	53	6	24	0
30 Sep 17	48	-11	23	43
30 Jun 17	12	-39	20	43
31 Mar 17	2	-61	19	43
31 Dec 16	6	-54	18	43
30 Sep 16	53	-11	19	11
30 Jun 16	55	1	20	23
31 Mar 16	57	-7	20	37
31 Dec 15	55	-21	21	50
30 Sep 15	12	-53	20	52
30 Jun 15	15	-67	20	53
31 Mar 15	18	-55	20	50
31 Dec 14	19	-38	20	51
30 Sep 14	27	-83	21	86
30 Jun 14	28	-99	21	54
31 Mar 14	29	-104	20	62
31 Dec 13	35	-124	18	47
30 Sep 13	30	-69	17	7
30 Jun 13	31	-67	17	35

Ingresos de calidad: XOMA actualmente no es rentable.

Margen de beneficios creciente: XOMA actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: XOMA no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 31.4% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de XOMA en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: XOMA no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-8.9%).

Rentabilidad financiera

Alta ROE: XOMA tiene una rentabilidad financiera negativa (-46.02%), ya que actualmente no es rentable.

XOMA Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings: EPS and revenues miss analyst expectations

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings released: US$0.59 loss per share (vs US$0.53 loss in 2Q 2022)

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Recent updates

XOMA Corporation (NasdaqGM:XOMA) completed the acquisition of Kinnate Biopharma Inc. (NasdaqGS:KNTE).

XOMA Corporation, Annual General Meeting, May 15, 2024

Is XOMA (NASDAQ:XOMA) Using Debt Sensibly?

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

Xoma Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

XOMA Corporation (NasdaqGM:XOMA) announces an Equity Buyback for $50 million worth of its shares.

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Consensus revenue estimates fall by 58%

Second quarter 2023 earnings released: US$0.59 loss per share (vs US$0.53 loss in 2Q 2022)

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 33%

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment improved over the past week

XOMA Corporation Appoints Owen Hughes as Interim Chief Executive Officer

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Price target increased to US$62.50

Consensus revenue estimates fall by 65%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Are Investors Undervaluing XOMA Corporation (NASDAQ:XOMA) By 49%?

Bearish: Analysts Just Cut Their XOMA Corporation (NASDAQ:XOMA) Revenue and EPS estimates

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

XOMA GAAP EPS of -$0.53 misses by $0.37, revenue of $0.98M misses by $3.29M

Investor sentiment deteriorated over the past week

CEO & Chairman of the Board exercised options and sold US$645k worth of stock

Investor sentiment improved over the past week

XOMA Corporation(NasdaqGM:XOMA) dropped from Russell 2000 Dynamic Index

Investor sentiment improved over the past week

Consensus revenue estimates fall by 14%

Consensus revenue estimates increase by 12%

Forecast: Analysts Think XOMA Corporation's (NASDAQ:XOMA) Business Prospects Have Improved Drastically

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to US$62.50

Now 24% undervalued

XOMA Corporation, Annual General Meeting, May 18, 2022

Investor sentiment improved over the past week

Now 20% undervalued

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2021 earnings released: US$0.51 loss per share (vs US$0.098 loss in 3Q 2020)

Investor sentiment improved over the past week

Price target increased to US$49.00

Price target decreased to US$46.00

Investor sentiment deteriorated over the past week

Xoma Gets The Spotlight

Things Look Grim For XOMA Corporation (NASDAQ:XOMA) After Today's Downgrade

Investor sentiment deteriorated over the past week

Consensus revenue estimates fall to US$9.98m

Consensus EPS estimates increase to -US$0.83

Second quarter 2021 earnings released: US$0.31 loss per share (vs US$0.33 loss in 2Q 2020)

Price target increased to US$52.33

CEO & Director recently sold US$303k worth of stock

Investor sentiment improved over the past week

We Think The Compensation For XOMA Corporation's (NASDAQ:XOMA) CEO Looks About Right

Consensus EPS estimates fall to -US$1.00

Does XOMA (NASDAQ:XOMA) Have A Healthy Balance Sheet?

First quarter 2021 earnings released: US$0.70 loss per share (vs US$0.49 loss in 1Q 2020)

XOMA EPS misses by $0.55, misses on revenue

XOMA gets milestone payment from Janssen Biotech

Investor sentiment improved over the past week

Key Executive exercised options to buy US$212k worth of stock.

XOMA's (NASDAQ:XOMA) Earnings Are Of Questionable Quality

Consensus revenue estimates increase to US$17.1m

Analysts Are More Bearish On XOMA Corporation (NASDAQ:XOMA) Than They Used To Be

Full year 2020 earnings released: EPS US$0.82 (vs US$0.23 loss in FY 2019)

Desglose de ingresos y gastos
Beta